Skip to Content
Missouri & Illinois Personal Injury Attorneys 800-391-4318

Serious birth defects linked to Zofran use


Zofran (Ondansetron) is an anti-nausea drug used to help cancer patients, and people who have recently had surgery. Zofran was approved by the FDA, yet is not for safe use in pregnant women. Sadly, many physicians have been prescribing the medication during pregnancy to ease women’s morning sickness side effects, but the results have been devastating. Now, many families are suing GlaxoSmithKline, the makers of Zofran, claiming negligence.

In 2012, GlaxoSmithKline settled a $3 billion settlement due to many civil and criminal charges alleging the company promoted Zofran, as well as many other off-label medications to physicians. Likewise, the company was offering monetary compensation to the physicians to amp up the prescriptions sales of such drugs, including Zofran. Tragically the pharmaceutical giant knew the damaging effects of Zofran use during pregnancy, yet chose to ignore such warnings.

Now, one woman in Chilton County, Alabama is claiming in a Zofran lawsuit, that the use of the drug caused several birth defects in her now, 8-year-old son, Talon. Furthermore, Talon was born with a high narrow pallet, extra fingers on his hands, a distended kidney, and glaucoma. Such debilitating birth defects have been following him through his life, and Talon now suffers seizures, is mute, and has delayed reactions. In addition,

Talon has been diagnosed with a chromosome defect called, Trisomy 13. Due to the diagnosis, GlaxoSmithKline is motioning to have the case thrown out because they can’t allege that Zofran use lead to Talon’s many abnormalities and thus Trisomy 13.

The experienced St. Louis personal injury attorneys at Meyerkord & Kurth are currently representing Zofran cases. If Zofran or any other drug has harmed you or a member of your family, please contact us today. We can help you recover from your traumatic experience and make sure you receive the fair financial compensation you deserve.

Share To: